Drug Profile
Research programme: inflammatory and autoimmune disease therapeutics - Palau Pharma
Alternative Names: DD-1; DD-2; DD-3Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Palau Pharma
- Class Small molecules
- Mechanism of Action Histamine H4 receptor antagonists; Janus kinase 3 inhibitors; Syk kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Atopic dermatitis; Autoimmune disorders; Inflammation
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Atopic-dermatitis in Spain
- 04 Nov 2017 No recent reports of development identified for preclinical development in Autoimmune-disorders in Spain (PO)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Inflammation in Spain (PO)